Research Paper Volume 13, Issue 4 pp 4999—5019

HOXB9 enhances the ability of lung cancer cells to penetrate the blood-brain barrier

class="figure-viewer-img"

Figure 1. HOXB9 is highly expressed in clinical NSCLC specimens and NSCLC cell lines and correlates with shorter patient survival. (A) Analysis of HOXB9 expression in NSCLC (n = 515) and normal lung tissue samples (n = 59) retrieved from the TCGA database. HOXB9 expression was significantly higher in NSCLC specimens (p<0.001). (B) High-HOXB9 expression is correlated with shorter overall survival (OS) in NSCLC (TCGA data). High-HOXB9 expression group, n = 127; low-HOXB9 expression group, n = 375; P = 0.025. (C) Representative images of HOXB9 expression from IHC analysis of 50 matched NSCLC and normal lung samples. Scale bars = 50 μm. (D) IHC score-based quantification of total HOXB9 IHC data from (C); HOXB9 expression was significantly higher in NSCLC samples (p<0.001). (E) Relative HOXB9 mRNA expression in NSCLC cell lines and human bronchial epithelial cells (HBE). (F) Western blotting analysis of HOXB9 expression in NSCLC cell lines and HBE cells, and the gray level analysis results for western blotting; *p < 0.05, **p < 0.01, ***p < 0.001.